CEL-SCI

CEL-SCI Corporation (NYSE American: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer, autoimmune and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances... CEL-SCI is a pioneer in cancer immunotherapy. Our global pivotal Phase III clinical trial in head and neck cancer tested the idea that we should boost the immune system of these patients when it is strongest, after diagnosis, BEFORE the ravages of standard of care therapy (surgery, radiation and chemotherapy). The Phase III trial is the largest ever in head and neck cancer with 928 patients enrolled. The top line data read out in June 2021 showed that when the Multikine treatment regimen was given after diagnosis before surgery and radiation (the first of two possible treatment arms determined by the treating physicians..

Also known as: Cel Sci Corp, CEL-SCI Corporation

Primary location: Vienna United States